Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: An updated retrospective study on local failure and survival rates

Figures & data

Table I. Patient characteristics.

	All patients	SBRT	Conventional RT	p-value
Gender
Female Male	65 67	55 45	10 22	N/S
Age (years) Mean Range Tumor volume mean (GTV, cm^3) Range Histology Adeno Squamous Others Smoking status Smoker or ex-smoker Never smoker Lung capacity FEV1, mean FEV1%, mean T-stage T1 T2 PS 0–1 2+	72.6 51–88 16.4 0.7–118 76 39 17 108 (82%) 24 (18%) 1.30 54 83 (63%) 49 (37%) 74 (56%) 58 (44%)	73.3 52–88 12.9 0.7–65 59 28 13 81 (81%) 19 (19%) 1.23 53 72 (72%) 28 (28%) 52 (52%) 48 (48%)	70.4 51–87 27.3 3–118 17 11 4 27 (84%) 5 (16%) 1.53 59 11 (34%) 21 (66%) 22 (69%) 10 (31%)	N/S < 0.001 N/S 0.011 N/S < 0.001 N/S
Staging-procedure CT-scan PET/CT EBUS/Mediastinoscopy Prescribed doses 80 Gy/35 F (BED 96 GY) 80 Gy/40 F (BED 98 GY) 45 Gy/3 F (BED 112 GY) 50 Gy/3 F (BED 133 GY) 66 Gy/3 F (BED 211 GY)	132 81 29	100 80 29 --- --- 32 1 67	32 1 0 20 12 --- --- ---
GTV, gross tumor volume	FEV1% - forced expiratory volume in 1 s of expected	Never smoker – stopped smoking > 10years ago

Figure 1. Kaplan-Meier survival curve of overall survival after convention radiation therapy and stereotactic body radiotherapy.

Table II. Cox multivariate regression analysis of factors affecting overall survival.

Overall survival	Relative risk (95% CI)	p-value
SBRT GTV < 25 cm^3 Adenocarcinoma Female gender Smoker PS > 1	0.56 (0.38–0.92) 1.14 (0.65–1.98) 1.08 (0.68–1.72) 0.51 (0.32–0.82) 0.81 (0.43–1.52) 1.80 (1.13–2.88)	0.020 N/S N/S 0.005 N/S 0.013

Figure 2. Kaplan-Meier survival curve of local-failure specific survival rates after convention radiation therapy and stereotactic body radiotherapy.